Anika Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $28,219 | $26,168 | $30,602 | $38,753 |
Gross Profit | 14,363 | 14,681 | 22,565 | 1,440 |
EBITDA | -2,465 | -2,692 | 1,473 | -25,423 |
EBIT | -3,965 | -4,284 | 38 | -27,611 |
Net Income | -3,970 | -4,873 | -21,865 | -29,918 |
Net Change In Cash | 28,219 | 26,168 | 30,602 | 38,753 |
Free Cash Flow | -1,656 | -2,954 | 275 | 3,800 |
Cash | 53,167 | 53,371 | 55,629 | 62,368 |
Basic Shares | 14,331 | 14,297 | 14,721 | 14,768 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $119,907 | $166,662 | $156,236 | $147,794 |
Gross Profit | 75,998 | 82,532 | 93,576 | 82,943 |
EBITDA | 3,020 | -11,232 | -4,913 | 2,302 |
EBIT | -5,101 | -25,449 | -19,400 | -12,015 |
Net Income | -56,385 | -82,667 | -14,859 | 4,134 |
Net Change In Cash | 119,907 | 166,662 | 156,236 | 147,794 |
Cost of Revenue | -7,929 | -1,500 | ||
Free Cash Flow | -2,331 | -7,215 | -3,077 | 3,254 |
Cash | 55,629 | 72,867 | 86,327 | 94,386 |
Basic Shares | 14,721 | 14,656 | 14,561 | 14,634 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-06-30 | -$0.13 |
2025-03-31 | -$0.06 |
2024-12-31 | -$0.03 |
2024-09-30 | -$0.25 |
